Injury to or neurodegeneration of the optic nerve underlies vision loss in many diseases, including glaucoma, ischemic and traumatic optic neuropathies, as well as retinal artery or vein occlusions, and many others. Normally, in humans and indeed in all mammals, there is no regenerative response, and the failure of injured or degenerating retinal ganglion cells (RGCs) to reconnect their axons through the optic nerve to their natural targets in the brain explains the irreversibility of such vision loss. A full white paper was published by these authors and is available on the National Eye Institute (NEI) Web site (in the public domain; available at https://nei.nih.gov/audacious/optic_nerve).

The National Eye Institute (NEI) hosted a workshop on November 19, 2014, as part of the Audacious Goals Initiative (AGI), an NEI-led effort to rapidly expand therapies for eye diseases through coordinated research funding. The central audacious goal aims to demonstrate by 2025 the restoration of usable vision in humans through the regeneration of neurons and neural connections in the eye and visual system. This workshop focused on identifying promising strategies for optic nerve regeneration. Its principal objective was to solicit input on future AGI-related funding announcements, and specifically to ask, where are we now in our scientific progress, and what progress should we reach for in the coming years? A full report was generated as a white paper posted on the NEI Web site; this report summarizes the discussion and outcomes from the meeting and serves as guidance for future funding of research that focuses on optic nerve regeneration.

Keywords: optic nerve, regeneration, goals, National Eye Institute, vision restoration

**STEPS TO OPTIC NERVE REGENERATION**

What will it take to restore vision in optic neuropathies, and what must happen to rescue an injured or dying RGC? Workshop participants outlined steps necessary for promoting successful optic nerve regeneration and restoration of vision.

**RGC Survival**

Survival is obviously a requirement for cellular or axon regeneration; thus, preventing RGCs from degeneration and subsequent death in the face of injury or disease is a critical first step. Retinal ganglion cell response to insult was also discussed, as the molecular pathophysiology of different insults, be they glaucomatous, ischemic, traumatic, inflammatory, or others, is still the subject of intense investigation. Although such questions hold great promise, developing therapeutic approaches to restore vision may not always require a complete understanding of the underlying causes of disease. Considerable progress in dissecting molecular pathways involved with RGC death in a number of preclinical models of human diseases has been made, although translational testing in humans with various optic neuropathies has been slow to follow.

A related area of considerable interest is RGC-type specificity. Retinal ganglion cells can be divided into different types based on morphology, receptive field properties, and more recently, by genetic markers. Important questions were
TABLE 1. Gaps in Knowledge and Other Unknowns

Lack of information about mechanisms underlying disease and injury-related regeneration

Why do retinal axons exhibit a weak capacity to regenerate? Are RGCs unique in their inability to regenerate?

How do retinal axons regenerate? What are the mechanisms of transport and trafficking?

Is regeneration of RGC type-specific?

What is the role of RGC activity after injury?

What are the relevant cues that guide long-range growth, target selection, and synapse formation?

How do nonneuronal factors, such as glia or extracellular matrices, influence regeneration?

Experimental models: standards and uniformity

Optic nerve crush (useful to evaluate regenerative therapies, but far less common in humans than ischemic or pressure-induced injuries)

Intraocular pressure (good for quantifying cell death and axon loss but less reproducible and more challenging for studying regenerative growth or restoration of vision)

Ischemic optic neuropathies (reproducible but less well studied)

Cell culture models

Timing of delivery of therapies, importance of finding "postinjury" efficacy

Comparative and standardization issues (age, onset of injury, response to injury)

Animal Models

Species selection: utility of fish, rabbit, rodent, non-human primate models

Need for translational bridges to humans

Early-phase human testing to help define goals and approaches

Outcomes

Behavioral assays linking structure to function

How many neural connections are enough?

Can "vision" areas be targeted?

identified as high priority: do different RGC types exhibit varying degrees of vulnerability to injury or disease? Do some types show more regenerative capacity than others?

Axon Growth

Both short (across an injury site) and long distance growth (back to central visual targets) must be addressed and may involve separate signaling pathways. Considerable progress has been made in identifying candidate molecules that stimulate axons to grow across an optic nerve injury site. Manipulation of local glial, vascular, and inflammatory responses all deserve additional attention, and testing combinatorial therapies and evaluating the quality of regenerative growth, including axon guidance, remain largely unexplored and should represent a major objective of the AGI. Indeed, the next major challenge is to encourage long distance growth to appropriate targets while minimizing aberrant growth and sprouting. While much progress has been made to understand the mechanisms underlying guidance, target selection, and synapse formation of developing axons, little is known about how regenerating axons perform after injury. Workshop participants generally dismissed the requirement that regenerative axon growth should necessarily recapitulate developmental patterning regarding pathway choice, target selection from the dozen different subcortical targets for regenerating RGCs to choose from, or specificity of synaptic connectivity. In regenerating axons, what steps need to be taken to prevent an aberrant projection from developing and innervating the spared/undamaged retina or inappropriate areas in the brain? Since target selection is cell-type specific, getting specific RGC types to innervate the appropriate target and become reintegrated into existing or remodeled circuits may be crucial, although questions on circuit reintegration in the adult are largely unstudied. Thus, it will be important to identify guidance cues and synapse formation signaling pathways in a regenerative environment. Indeed, some axon growth-promoting regenerative therapies may introduce guidance or synapse formation problems, while others may not, suggesting that all regenerative therapies may not be equal. Within this context, however, there was discussion that RGC innervation of brain targets subserving image formation may be more important than promoting regeneration of RGCs dedicated to non-image-forming functions such as pupillary light response or photoentrainment of circadian rhythm.

GAPS IN SCIENTIFIC KNOWLEDGE AND BARRIERS TO PROGRESS

The workshop’s subsequent focus was to identify and elaborate on the present gaps of knowledge in the area of optic nerve regeneration; these are summarized in Table 1. Closely related to these gaps in knowledge was the discussion of which of these are significant barriers to progress, summarized in Table 2. Overcoming these gaps will help bring scientists together across disciplines to make major progress toward optic nerve regeneration and vision restoration.

TRANSLATION TO HUMAN DISEASE

Perhaps most limiting in reaching the goal of restoring vision in humans is the lack of translational research and early phase human testing in RGC survival and regeneration. Research across other body systems has already demonstrated that human testing is extremely important, and certainly human patients with optic nerve diseases are eager to participate in appropriately vetted trials of new therapeutic candidates. Such initial testing of candidate therapies in humans will begin to address critical questions, such as: How important are fine points of circuit integration? Is it enough to give someone light perception or improve contrast sensitivity? Functional im-
provement is a big step, but it will also be necessary to perform human trials to learn how to measure axon regeneration and visual restoration in patients. Similarly, the workshop participants noted that, as a field, we should think backwards from the “clinic-of-the-future.” Having biomarkers for RGC function will be extremely important, as will having a delivery system with demonstrated safety. Moving treatments into human testing was identified as something that could be done quickly, within 5 years, and would help the field determine how to conduct clinical trials in a shorter time frame.

A VIEW TO THE FUTURE

Based on workshop consensus, immediate goals should include extending work to enhance regeneration in current animal models, solving axon guidance and central targeting in regeneration, and crossing into human testing for both validating biomarkers and testing candidate therapies. Other first-move approaches should include building resource centers and expanding functional or behavioral testing assays in preclinical models. The group appreciated that although disease pathophysiology remains an important separate goal, one therapeutic solution might ultimately address many different optic neuropathies, and that identifying candidate therapies should be a major focus of the AGI.

Acknowledgments

The authors are grateful for support from the National Eye Institute (EY022129 and EY012716), the Department of Defense Congresionally Directed Medical Research Program (W81XWH-12-1-0254), and Research to Prevent Blindness, Inc.

Disclosure: J.L. Goldberg, None; W. Guido, None

References


APPENDIX

AGI Workshop Participants

Aileen Anderson, PhD, Professor, University of California, Associate Director, Sue and Bill Gross Stem Cell Research Center, Director, Reeve Foundation Spinal Cord Injury Core Facility, Institute for Memory Impairments and Neurological Disorders, Reeve-Irvine Research Center, Institute for Immunology, University of California, Irvine, California, United States; aja@uci.edu.

Larry Benowitz, PhD, Professor, Departments of Neurosurgery and Ophthalmology, Laboratory of Neuroscience Research for Neuroscience Research, F. M. Kirby Neurobiology Center, Boston Children’s Hospital, Harvard Medical School, Boston, Massachusetts, United States; larry.benowitz@childrens.harvard.edu.

Deanna Benson, PhD, Professor, Department of Neuroscience, Friedman Institute, Icahn School of Medicine at Mount Sinai, New York, New York, United States; deanna.benson@msm.edu.

Kapil Bharti, PhD, Earl Stadtman Tenure-Track Investigator, National Eye Institute, National Institutes of Health, Bethesda, Maryland, United States; kapilbharti@nei.nih.gov.

Mark Blumenkranz, MD (AGI Steering Committee). H. J. Smed Professor, Department of Ophthalmology, Stanford University, Palo Alto, California, United States; mark.blumenkranz@stanford.edu.

Brian Brooks, MD, PhD, Chief, Ophthalmic Genetics Branch and Visual Function Branch, National Eye Institute, National Institutes of Health, Bethesda, Maryland, United States; brooksbl@mail.nih.gov.

Martha Constantine-Paton, PhD, Professor, Departments of Brain and Cognitive Science and Biology, Investigator, McGovern Institute for Brain Research, Massachusetts Institute of Technology, Cambridge, Massachusetts, United States; mcpaton@mit.edu.

Michael Crair, PhD, Professor, Departments of Neurobiology and Ophthalmology & Visual Science, Director of Vision Core Program, Yale University, New Haven, Connecticut, United States; michael.crair@yale.edu.

Jeffrey Diamond, PhD, Senior Investigator, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, United States; diamondj@ninds.nih.gov.

John Dowling, PhD, AB (AGI Steering Committee), Gordon and Llura Gund Professor of Neurosciences, Professor of Ophthalmology, Harvard Medical School, Harvard University, Boston, Massachusetts, United States; dowling@mch.harvard.edu.

James Fawcett, MD, PhD, Professor, Department of Clinical Neurosciences, Cambridge Centre for Brain Repair, University of Cambridge, Cambridge, England; jf108@cam.ac.uk.

David Feldheim, PhD, Professor, Department of Molecular, Cell, and Developmental Biology, University of California, Santa Cruz, Santa Cruz, California, United States; feldheim@biology.ucsc.edu.

Laura Frishman, PhD, Professor, College of Optometry, University of Houston, Houston, Texas, United States; lfrishman@uh.edu.

Jeffrey Goldberg, MD, PhD (Co-Chair),* Professor and Director of Research, Shiley Eye Center, Department of Ophthalmology, University of California, San Diego, California, United States; *Current affiliation, Professor and Chair, Byers Eye Institute, Department of Ophthalmology, Stanford University, Palo Alto, California, United States; jeffrey.goldberg@stanford.edu.
National Institutes of Health, Bethesda, Maryland, United States; pas@nei.nih.gov.

Richard Masland, PhD, Professor of Ophthalmology, Massachusetts Eye and Ear Infirmary, Professor of Neurobiology, Harvard Medical School, Boston, Massachusetts, United States; richard_masland@meei.harvard.edu.

Robert Nickells, PhD, Professor and Vice Chair for Research, Department of Ophthalmology and Visual Sciences, University of Wisconsin, Madison, Wisconsin, United States; nickells@wisc.edu.

Pamela Raymond, PhD (AGI Steering Committee), Stephen S. Easter Collegiate Professor, Department of Molecular, Cellular, and Developmental Biology, College of Literature, Science, and the Arts, University of Michigan, Ann Arbor, Michigan, United States; praymond@umich.edu.

Joshua Sanes, PhD (AGI Steering Committee), Director, Center for Brain Science, Professor, Department of Molecular and Cellular Biology, Harvard University, Boston, Massachusetts, United States; sanes@mcb.harvard.edu.

Paul A. Sieving, MD, PhD, Director, National Eye Institute, National Institutes of Health, Bethesda, Maryland, United States; pas@nei.nih.gov.

Stephen Strittmatter, MD, PhD, Professor of Neurology and Neurobiology, Director of Cellular Neuroscience, Neurodegeneration, and Repair, Yale University, New Haven, Connecticut, United States; stephen.strittmatter@yale.edu.

Veronica Tom, PhD, Assistant Professor, Department of Neurobiology and Anatomy, Drexel University, Philadelphia, Pennsylvania, United States; vtom@drexelmed.edu.

W. Martin Usrey, PhD, Professor, Center for Neuroscience, University of California, Davis, California, United States; wusrey@ucdavis.edu.

Robert Wurtz, PhD, Chief, Visuomotor Integration Section, Laboratory of Sensorimotor Research, National Eye Institute, National Institutes of Health, Bethesda, Maryland, United States; bob@lre.nei.nih.gov.

Rafael Yuste, MD, PhD, Director, Neurotechnology Center, Columbia University, New York, New York, United States; rmy@columbia.edu.

Don Zack, MD, PhD, Professor, Wilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland, United States; donorack@gmail.com.

Fengjuan Zhou, PhD, Associate Professor, Departments of Ophthalmic Surgery and Neuroscience, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States; fzhou4@jhmi.edu.

**NEI Staff – Division of Extramural Research and Office of the Director**

Neeraj Agarwal, PhD, Program Director, Glaucoma and Optic Neuropathies, Division of Extramural Research, National Eye Institute, National Institutes of Health, Bethesda, Maryland, United States; agarwalnee@nei.nih.gov.

Houman Araj, PhD, Program Director, Lens and Cataract, Oculomotor Systems and Neuro-Ophthalmology, Division of Extramural Research, National Eye Institute, National Institutes of Health, Bethesda, Maryland, United States; arraj@mail.nih.gov.

Steven Becker, PhD, AGI Liaison, Special Assistant to the Office of the Director, National Eye Institute, National Institutes of Health, Bethesda, Maryland, United States; beckersteven@nei.nih.gov.

Kathryn DeMott, Science Writer, Office of Science Communications, Public Liaison & Education, National Eye Institute, National Institutes of Health, Bethesda, Maryland, United States; kathy.demott@nih.gov.

Mala Dutta, PhD, Presidential Management Fellow, Office of Translational Research, National Eye Institute, National Institutes of Health, Bethesda, Maryland, United States; mala.dutta@nih.gov.

Donald Everett, MA, Program Director, Collaborative Clinical Research, Division of Extramural Research, National Eye Institute, National Institutes of Health, Bethesda, Maryland, United States; deverett@nei.nih.gov.

Shefa Gordon, PhD, Acting Director, Office of Program Planning and Analysis, National Eye Institute, National Institutes of Health, Bethesda, Maryland, United States; shefa@nei.nih.gov.

Thomas Greenwell, PhD, Program Director, Retinal Neuroscience, Division of Extramural Research, National Eye Institute, National Institutes of Health, Bethesda, Maryland, United States; greenwell@nei.nih.gov.

Dustin C. Hays, Science Writer, Office of Science Communications, Public Liaison & Education, National Eye Institute, National Institutes of Health, Bethesda, Maryland, United States; dustin.hays@nih.gov.

Brian Hoshaw, PhD, Scientific Review Officer, Scientific Review Branch, National Eye Institute, National Institutes of Health, Bethesda, Maryland, United States; hoshawb@nei.nih.gov.

Jeanette Hosseini, PhD, Scientific Review Officer, Scientific Review Branch, National Eye Institute, National Institutes of Health, Bethesda, Maryland, United States; jeanette.hosseini@nih.gov.

Lyn Jakeman, PhD, Program Director, Spinal Cord Injury and Nerve Repair, Repair and Plasticity Cluster, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, United States; lyn.jakeman@nih.gov.

Ellen Liberman, PhD, MBA, NEI Extramural Policy Officer, Center Core Grants, Division of Extramural Research, National Eye Institute, National Institutes of Health, Bethesda, Maryland, United States; esl@nei.nih.gov.

Matt McMahon, PhD, Director, Office of Translational Research, National Eye Institute, National Institutes of Health, Bethesda, Maryland, United States; mm@nigh.gov.

Lisa A. Neuhold, PhD, Program Director, Fundamental Retinal Processes, Division of Extramural Research, National Institute of...
Eye Institute, National Institutes of Health, Bethesda, Maryland, United States; ineuhold@mail.nih.gov.

Anne Schaffner, PhD, Chief, Scientific Review Branch, Interim Executive Secretary of the National Advisory Eye Council, National Eye Institute, National Institutes of Health, Bethesda, Maryland, United States; aes@nei.nih.gov.

Belinda Seto, PhD, Deputy Director, National Eye Institute, National Institutes of Health, Bethesda, Maryland, United States; setob@nei.nih.gov.

Grace Shen, PhD, Program Director, Retinal Diseases, Division of Extramural Research, National Eye Institute, National Institutes of Health, Bethesda, Maryland, United States; sheng@mail.nih.gov.

Michael Steinmetz, PhD, Acting Director, Division of Extramural Research, Program Director, Strabismus, Amblyopia, and Visual Processing, National Eye Institute, National Institutes of Health, Bethesda, Maryland, United States; michael.steinmetz@nih.gov.

Daniel Stimson, PhD, Acting Director, Office of Science Communications, Public Liaison & Education, National Eye Institute, National Institutes of Health, Bethesda, Maryland, United States; daniel.stimson@nih.gov.

Cheri Wiggs, PhD, Program Director, Perception and Psychophysics, Low Vision and Blindness Rehabilitation, Division of Extramural Research, National Eye Institute, National Institutes of Health, Bethesda, Maryland, United States; cheri.wiggs@nih.gov.